HAS-BLED Score
Calculate HAS-BLED score for 1-year major bleeding risk assessment in AF patients on anticoagulation. Get criteria breakdown, risk category, and management recommendations.
About This Calculator
The HAS-BLED score calculator is a clinically validated risk stratification tool designed to estimate the 1-year risk of major bleeding in patients with atrial fibrillation (AF) who are receiving anticoagulation therapy. Developed by Pisters et al. in 2010 from the Euro Heart Survey of 3,978 patients, it provides a simple, user-friendly approach to bleeding risk assessment that complements the CHA₂DS₂-VASc score for stroke risk evaluation. The score evaluates nine clinical criteria corresponding to the HAS-BLED acronym: Hypertension (uncontrolled systolic BP >160 mmHg), Abnormal renal function (dialysis, transplant, or serum creatinine >2.26 mg/dL or >200 μmol/L) and Abnormal liver function (cirrhosis, bilirubin >2x normal, or AST/ALT/AP >3x normal), Stroke history, Bleeding history or predisposition, Labile INR (time in therapeutic range <60%), Elderly age (>65 years), and Drugs (antiplatelet agents or NSAIDs) and alcohol excess (≥8 drinks per week).
Each criterion contributes 1 point, with the A (abnormal renal/liver) and D (drugs/alcohol) categories having two sub-criteria each that can contribute up to 2 points total. The total score ranges from 0 to 9, with higher scores indicating greater bleeding risk. A score of 0 to 1 is classified as low risk, 2 as moderate risk, and 3 or higher as high risk. The major bleeding risk per 100 patient-years ranges from approximately 1.02% at score 1 to 12.50% at score 5 and above. Major bleeding is defined as intracranial hemorrhage, hospitalization due to bleeding, hemoglobin decrease >2 g/dL, and/or requiring blood transfusion.
Clinical decision-making based on the HAS-BLED score should be integrated with stroke risk assessment. A high HAS-BLED score does not automatically preclude anticoagulation but signals the need for close monitoring, regular review, and management of modifiable risk factors. The 2020 ESC Guidelines for atrial fibrillation specifically recommend the HAS-BLED score for bleeding risk assessment. Modifiable risk factors that can reduce bleeding risk include better hypertension control, reducing alcohol consumption, minimizing NSAID and antiplatelet use, and improving INR control (TTR >70%).
Regional Notes
India: The HAS-BLED score is used in Indian cardiology practice following international AF management guidelines. Indian AF patients often present at a younger age with higher rates of rheumatic heart disease. Anticoagulation decisions should consider local epidemiology, availability of DOACs, and INR monitoring infrastructure. The score provides a useful framework for discussions about bleeding risk with patients.
United States: The AHA/ACC guidelines acknowledge the HAS-BLED score for bleeding risk assessment in AF patients. DOACs are first-line therapy for eligible patients, and the score helps guide decisions about anticoagulation intensity. Medicare and most insurers cover anticoagulation based on CHA₂DS₂-VASc and HAS-BLED assessment.
United Kingdom: NICE guidelines recommend formal bleeding risk assessment before starting anticoagulation. The HAS-BLED score is one of the recommended tools. The NHS uses it alongside CHA₂DS₂-VASc for comprehensive AF management. DOACs are available on the NHS for eligible patients after risk-benefit assessment.
Frequently Asked Questions
What is the HAS-BLED score?
The HAS-BLED score is a validated medical risk stratification tool developed in 2010 to assess the 1-year risk of major bleeding in patients with atrial fibrillation who are on anticoagulation therapy. The acronym stands for Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly (age >65), and Drugs or alcohol excess. The score ranges from 0 to 9, with higher scores indicating greater bleeding risk.
How is the HAS-BLED score calculated?
The HAS-BLED score assigns 1 point each for nine conditions: hypertension (uncontrolled BP >160 mmHg systolic), abnormal renal function (dialysis, transplant, or Cr >2.26 mg/dL), abnormal liver function (cirrhosis or bilirubin >2x normal or AST/ALT/AP >3x normal), prior stroke history, prior major bleeding or predisposition, labile INR (TTR <60%), age over 65 years, medication use (antiplatelets or NSAIDs), and alcohol excess (≥8 drinks per week). The total score ranges from 0 to 9.
What does a high HAS-BLED score mean?
A HAS-BLED score of 3 or higher indicates high risk of major bleeding and warrants caution. It signals the need for regular clinical review and close monitoring of anticoagulation therapy. Modifiable risk factors such as hypertension control, reducing alcohol intake, and minimizing NSAID use should be addressed. However, a high score does not automatically mean anticoagulation cannot be used — the stroke risk (assessed by CHA2DS2-VASc score) must be weighed against the bleeding risk.
Is the HAS-BLED score used alongside the CHA2DS2-VASc score?
Yes, the HAS-BLED score is used together with the CHA2DS2-VASc score for comprehensive atrial fibrillation management. While CHA2DS2-VASc assesses ischemic stroke risk to determine who needs anticoagulation, the HAS-BLED score evaluates the risk of major bleeding from anticoagulation therapy. The 2020 ESC guidelines recommend using HAS-BLED as a simple, easy calculation for bleeding risk assessment in all AF patients.
What are the components of the HAS-BLED acronym?
HAS-BLED stands for: H — Hypertension (uncontrolled, >160 mmHg systolic), A — Abnormal renal and liver function (1 point each), S — Stroke (prior history), B — Bleeding (prior major bleeding or predisposition), L — Labile INR (unstable/high, TTR <60%), E — Elderly (age >65 years), D — Drugs (antiplatelets, NSAIDs) and alcohol excess (≥8 drinks/week). Each component contributes 1 point, with the A and D categories each having two sub-criteria that can contribute up to 2 points total.
Can the HAS-BLED score be used for patients not on warfarin?
Yes, the HAS-BLED score has been validated in patients on direct oral anticoagulants (DOACs) as well as those on warfarin. However, the 'L' component (labile INR) specifically applies to warfarin users and may score 0 for patients on DOACs where INR monitoring is not routinely performed. The score still provides useful bleeding risk stratification regardless of the specific anticoagulant used.
Is the HAS-BLED score used in India, the US, and the UK?
Yes, the HAS-BLED score is used internationally across India, the US, and the UK. The 2020 ESC guidelines for atrial fibrillation recommend its use for bleeding risk assessment. In the US, the AHA/ACC guidelines acknowledge its utility alongside the CHA2DS2-VASc score. In the UK, NICE guidelines recommend bleeding risk assessment in AF patients. Indian cardiology practice follows these international guidelines, though local risk profiles and anticoagulant availability may influence clinical decisions.
What is the annual major bleeding risk for each HAS-BLED score?
Based on the original Euro Heart Survey validation cohort (2010), the annual major bleeding risk per 100 patients increases with the HAS-BLED score: score 0 = ~1.13%, score 1 = ~1.02%, score 2 = ~1.88%, score 3 = ~3.74%, score 4 = ~8.70%, score 5 = ~12.50%. Scores of 6 or higher carry approximately 12.50% annual risk. These rates help guide clinical decisions about anticoagulation therapy intensity and monitoring frequency.